Allovir, INC

Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, while Brett Hagen resigns as Chief Accounting Officer.

Kalaris Therapeutics announced positive additional data from its Phase 1a SAD clinical trial of TH103 for neovascular age-related macular degeneration (nAMD), showing improvements in vision and retinal anatomy.

Kalaris Therapeutics announced the resignation of director Morana Jovan-Embiricos and the election of Laurie Keating to the board and audit committee, effective August 1, 2026.

Kalaris Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of new directors and the ratification of its independent auditor.

Kalaris Therapeutics reports Q1 2026 financial results, highlighting $104.9 million in cash reserves and progress in its Phase 1b/2 study for TH103.

Kalaris Therapeutics announced the resignation of its Chief Financial Officer, Matthew Gall, effective April 14, 2026, with Chief Accounting Officer Brett Hagen assuming principal financial officer duties.

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported Q3 2025 financial results, highlighting progress in its TH103 clinical trials and a strengthened cash position following its merger with AlloVir.

Kalaris Therapeutics reports increased losses and cash burn in Q2 2025, despite a significant cash infusion from its merger with AlloVir, as it advances its lead retinal disease candidate TH103.

Kalaris Therapeutics reports its first quarterly results post-merger with AlloVir, highlighting key executive employment agreements and ongoing clinical trial developments.

AlloVir, a clinical-stage cell therapy company, has entered into a merger agreement with Kalaris Therapeutics after discontinuing Phase 3 trials and undergoing a strategic review.

AlloVir, a clinical-stage cell therapy company, released its Q2 2024 financial results, highlighting a significant reduction in operating expenses due to the discontinuation of clinical trials and a strategic review process.

AlloVir, a clinical-stage cell therapy company, announced its first quarter 2024 financial results, highlighting a significant reduction in operating expenses due to a strategic review and workforce reduction.

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses in 2025 while advancing its lead product candidate, TH103, for retinal diseases with promising early clinical data.

AlloVir plans to merge with Kalaris Therapeutics following the discontinuation of its Phase 3 trials, seeking to maximize shareholder value and trade under the ticker symbol KLRS upon completion.

AlloVir halts Phase 3 trials for posoleucel, initiates strategic review, and reduces workforce by 95% to preserve capital.

Laurie Keating, a Director of Allovir, Inc., received 18,000 shares of common stock on August 1, 2026.

Liisa Ann Bayko, Chief Financial Officer of Allovir, Inc., received 220,000 shares of common stock on July 20, 2026.

Director Morana Jovan-Embiricos was granted 9,000 stock options in Kalaris Therapeutics, Inc. with an exercise price of $4.72.

Director Napoleone Ferrara was granted 9,000 stock options in Kalaris Therapeutics, Inc. on June 3, 2026.

Director David Hallal was granted 9,000 stock options in Kalaris Therapeutics, Inc. with an exercise price of $4.72.

Director Srinivas Akkaraju was granted 9,000 stock options in Kalaris Therapeutics, Inc. as part of a standard equity compensation arrangement.

Kalaris Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 3, 2026.

Kalaris Therapeutics, Inc. has announced its Annual Meeting of Stockholders for August 12, 2025, to vote on the election of two Class II directors and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm.

Kalaris Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on August 12, 2025, where shareholders will vote on director elections and auditor ratification, following its recent merger with Legacy Kalaris Tx, Inc.

AlloVir is asking shareholders to approve a reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.

AlloVir, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024, with voting open until June 5, 2024.

AlloVir, Inc. is set to hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Samsara BioCapital reports internal share transfers and distributions among its affiliated funds regarding Kalaris Therapeutics.

Samsara BioCapital and its affiliates, led by Srinivas Akkaraju, increased their beneficial ownership in Kalaris Therapeutics to 56.5% following a $15 million investment in a private placement.

Samsara BioCapital, L.P., along with its general partner and managing member, has reported beneficial ownership of 61.2% of Kalaris Therapeutics, Inc. common stock following a recent merger.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have reported a 5.7% beneficial ownership stake in Kalaris Therapeutics, Inc. as of December 31, 2025.

Invus Public Equities and its affiliated entities, including Invus Public Equities Advisors, Invus Global Management, Siren, and Raymond Debbane, continue to collectively hold a 1.5% beneficial ownership in Kalaris Therapeutics, Inc.

EcoR1 Capital, LLC and affiliated entities have filed an amended Schedule 13G, reporting a 1.1% beneficial ownership stake in Kalaris Therapeutics, Inc. as of March 31, 2025.

Gilead Sciences, Inc. has filed an amended Schedule 13G, disclosing a 3.9% beneficial ownership stake in Kalaris Therapeutics, Inc., which recently completed a merger and changed its name and ticker symbol.

EcoR1 Capital, LLC and its affiliates have disclosed a beneficial ownership of 8.1% in Allovir, Inc.'s common stock as of December 31, 2024, following a recent 1-for-23 reverse stock split.